25 XP   0   0   10

Kinnate Biopharma Inc
Buy, Hold or Sell?

Let's analyse Kinnate together

PenkeI guess you are interested in Kinnate Biopharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Kinnate Biopharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Kinnate Biopharma Inc

I send you an email if I find something interesting about Kinnate Biopharma Inc.

Quick analysis of Kinnate (30 sec.)










What can you expect buying and holding a share of Kinnate? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$3.38
Expected worth in 1 year
$-5.03
How sure are you?
33.3%

+ What do you gain per year?

Total Gains per Share
$-8.41
Return On Investment
-317.3%

For what price can you sell your share?

Current Price per Share
$2.65
Expected price per share
$2.2 - $2.95
How sure are you?
50%

1. Valuation of Kinnate (5 min.)




Live pricePrice per Share (EOD)

$2.65

Intrinsic Value Per Share

$-31.88 - $-28.48

Total Value Per Share

$-28.51 - $-25.10

2. Growth of Kinnate (5 min.)




Is Kinnate growing?

Current yearPrevious yearGrowGrow %
How rich?$159.3m$258.4m-$99.1m-62.2%

How much money is Kinnate making?

Current yearPrevious yearGrowGrow %
Making money-$112.6m-$114m$1.3m1.2%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Kinnate (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#289 / 1010

Most Revenue
#761 / 1010

Most Profit
#766 / 1010

Most Efficient
#204 / 1010

What can you expect buying and holding a share of Kinnate? (5 min.)

Welcome investor! Kinnate's management wants to use your money to grow the business. In return you get a share of Kinnate.

What can you expect buying and holding a share of Kinnate?

First you should know what it really means to hold a share of Kinnate. And how you can make/lose money.

Speculation

The Price per Share of Kinnate is $2.65. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Kinnate.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Kinnate, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.38. Based on the TTM, the Book Value Change Per Share is $-2.10 per quarter. Based on the YOY, the Book Value Change Per Share is $-2.04 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Kinnate.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-2.39-90.1%-2.39-90.1%-2.47-93.0%-1.55-58.3%-1.31-49.6%
Usd Book Value Change Per Share-2.10-79.3%-2.10-79.3%-2.04-76.8%0.6424.3%0.5621.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-2.10-79.3%-2.10-79.3%-2.04-76.8%0.6424.3%0.5621.2%
Usd Price Per Share2.37-2.37-6.10-13.19-11.00-
Price to Earnings Ratio-0.99--0.99--2.47--13.05--10.87-
Price-to-Total Gains Ratio-1.13--1.13--3.00--5.28--5.28-
Price to Book Ratio0.70-0.70-1.11-1.79-1.49-
Price-to-Total Gains Ratio-1.13--1.13--3.00--5.28--5.28-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.65
Number of shares377
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-2.100.64
Usd Total Gains Per Share-2.100.64
Gains per Quarter (377 shares)-792.43242.53
Gains per Year (377 shares)-3,169.73970.14
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-3170-31800970960
20-6339-6350019401930
30-9509-9520029102900
40-12679-12690038813870
50-15849-15860048514840
60-19018-19030058215810
70-22188-22200067916780
80-25358-25370077617750
90-28528-28540087318720
100-31697-31710097019690

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.06.00.00.0%0.06.00.00.0%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%2.04.00.033.3%2.04.00.033.3%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.06.00.0%0.00.06.00.0%
Total Gains per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%2.04.00.033.3%2.04.00.033.3%

Fundamentals of Kinnate

About Kinnate Biopharma Inc

Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

Fundamental data was last updated by Penke on 2024-04-11 12:43:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Kinnate Biopharma Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Kinnate earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Kinnate to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Kinnate Biopharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.2%+207.2%
TTM--218.5%+218.5%
YOY--284.8%+284.8%
5Y--435.1%+435.1%
10Y--589.3%+589.3%
1.1.2. Return on Assets

Shows how efficient Kinnate is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Kinnate to the Biotechnology industry mean.
  • -64.9% Return on Assets means that Kinnate generated $-0.65 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Kinnate Biopharma Inc:

  • The MRQ is -64.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -64.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-64.9%TTM-64.9%0.0%
TTM-64.9%YOY-40.9%-24.0%
TTM-64.9%5Y-30.9%-34.0%
5Y-30.9%10Y-41.5%+10.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-64.9%-13.2%-51.7%
TTM-64.9%-12.7%-52.2%
YOY-40.9%-11.5%-29.4%
5Y-30.9%-13.8%-17.1%
10Y-41.5%-15.5%-26.0%
1.1.3. Return on Equity

Shows how efficient Kinnate is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Kinnate to the Biotechnology industry mean.
  • -70.7% Return on Equity means Kinnate generated $-0.71 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Kinnate Biopharma Inc:

  • The MRQ is -70.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -70.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-70.7%TTM-70.7%0.0%
TTM-70.7%YOY-51.0%-19.7%
TTM-70.7%5Y-31.7%-39.0%
5Y-31.7%10Y-43.2%+11.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-70.7%-16.8%-53.9%
TTM-70.7%-16.0%-54.7%
YOY-51.0%-14.8%-36.2%
5Y-31.7%-19.3%-12.4%
10Y-43.2%-20.0%-23.2%

1.2. Operating Efficiency of Kinnate Biopharma Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Kinnate is operating .

  • Measures how much profit Kinnate makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Kinnate to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Kinnate Biopharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.8%+299.8%
TTM--239.2%+239.2%
YOY--295.4%+295.4%
5Y--485.9%+485.9%
10Y--624.6%+624.6%
1.2.2. Operating Ratio

Measures how efficient Kinnate is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Kinnate Biopharma Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.238-3.238
TTM-3.313-3.313
YOY-3.838-3.838
5Y-5.675-5.675
10Y-7.612-7.612

1.3. Liquidity of Kinnate Biopharma Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Kinnate is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 13.19 means the company has $13.19 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Kinnate Biopharma Inc:

  • The MRQ is 13.187. The company is very able to pay all its short-term debts. +2
  • The TTM is 13.187. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ13.187TTM13.1870.000
TTM13.187YOY13.447-0.260
TTM13.1875Y28.426-15.239
5Y28.42610Y26.571+1.855
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.1873.870+9.317
TTM13.1874.173+9.014
YOY13.4475.332+8.115
5Y28.4266.126+22.300
10Y26.5716.448+20.123
1.3.2. Quick Ratio

Measures if Kinnate is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Kinnate to the Biotechnology industry mean.
  • A Quick Ratio of 20.93 means the company can pay off $20.93 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Kinnate Biopharma Inc:

  • The MRQ is 20.931. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 20.931. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ20.931TTM20.9310.000
TTM20.931YOY21.768-0.837
TTM20.9315Y33.440-12.509
5Y33.44010Y30.749+2.691
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ20.9313.510+17.421
TTM20.9313.994+16.937
YOY21.7685.357+16.411
5Y33.4406.105+27.335
10Y30.7496.404+24.345

1.4. Solvency of Kinnate Biopharma Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Kinnate assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Kinnate to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.08 means that Kinnate assets are financed with 8.2% credit (debt) and the remaining percentage (100% - 8.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Kinnate Biopharma Inc:

  • The MRQ is 0.082. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.082. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.082TTM0.0820.000
TTM0.082YOY0.073+0.009
TTM0.0825Y0.287-0.204
5Y0.28710Y0.248+0.038
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0820.339-0.257
TTM0.0820.336-0.254
YOY0.0730.271-0.198
5Y0.2870.368-0.081
10Y0.2480.388-0.140
1.4.2. Debt to Equity Ratio

Measures if Kinnate is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Kinnate to the Biotechnology industry mean.
  • A Debt to Equity ratio of 9.0% means that company has $0.09 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Kinnate Biopharma Inc:

  • The MRQ is 0.090. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.090. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.090TTM0.0900.000
TTM0.090YOY0.091-0.001
TTM0.0905Y0.048+0.042
5Y0.04810Y0.050-0.002
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0900.390-0.300
TTM0.0900.402-0.312
YOY0.0910.339-0.248
5Y0.0480.428-0.380
10Y0.0500.461-0.411

2. Market Valuation of Kinnate Biopharma Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Kinnate generates.

  • Above 15 is considered overpriced but always compare Kinnate to the Biotechnology industry mean.
  • A PE ratio of -0.99 means the investor is paying $-0.99 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Kinnate Biopharma Inc:

  • The EOD is -1.110. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.992. Based on the earnings, the company is expensive. -2
  • The TTM is -0.992. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.110MRQ-0.992-0.117
MRQ-0.992TTM-0.9920.000
TTM-0.992YOY-2.475+1.482
TTM-0.9925Y-13.049+12.057
5Y-13.04910Y-10.874-2.175
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.110-2.296+1.186
MRQ-0.992-2.600+1.608
TTM-0.992-2.726+1.734
YOY-2.475-4.145+1.670
5Y-13.049-6.259-6.790
10Y-10.874-6.348-4.526
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Kinnate Biopharma Inc:

  • The EOD is -1.249. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.117. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.117. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.249MRQ-1.117-0.132
MRQ-1.117TTM-1.1170.000
TTM-1.117YOY-3.136+2.018
TTM-1.1175Y-15.490+14.373
5Y-15.49010Y-12.908-2.582
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.249-2.937+1.688
MRQ-1.117-3.326+2.209
TTM-1.117-3.553+2.436
YOY-3.136-5.605+2.469
5Y-15.490-8.385-7.105
10Y-12.908-8.882-4.026
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Kinnate is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.70 means the investor is paying $0.70 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Kinnate Biopharma Inc:

  • The EOD is 0.784. Based on the equity, the company is cheap. +2
  • The MRQ is 0.702. Based on the equity, the company is cheap. +2
  • The TTM is 0.702. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.784MRQ0.702+0.083
MRQ0.702TTM0.7020.000
TTM0.702YOY1.113-0.412
TTM0.7025Y1.789-1.087
5Y1.78910Y1.491+0.298
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.7841.909-1.125
MRQ0.7022.114-1.412
TTM0.7022.096-1.394
YOY1.1132.884-1.771
5Y1.7893.554-1.765
10Y1.4913.938-2.447
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Kinnate Biopharma Inc.

3.1. Institutions holding Kinnate Biopharma Inc

Institutions are holding 82.583% of the shares of Kinnate Biopharma Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Foresite Capital Management IV, LLC20.505411.5841967164300
2023-12-31Orbimed Advisors, LLC16.98180.3791800972900
2023-12-31Foresite Capital Management V, LLC7.475611.3862352595700
2023-12-31Vida Ventures Advisors, LLC4.68086.2293220777200
2023-12-31Viking Global Investors LP3.85970.0158182046200
2023-09-30Citadel Advisors Llc2.2470.00031059843-26543-2.4432
2023-12-31Vanguard Group Inc2.21110.00011042910486984.8982
2023-12-31Acadian Asset Management LLC1.76080.00768304939380712.7336
2023-12-31BlackRock Inc1.24390586688-154662-20.8622
2023-12-31Renaissance Technologies Corp1.2190.00215749796902313.6421
2023-12-31Millennium Management LLC1.19770.000656493276741.3771
2023-12-31Group One Trading, LP1.19480.0035563565563265187755
2023-12-31BML Capital Management LLC0.99270.84054682104682100
2023-09-30Jacobs Levy Equity Management, Inc.0.95290.0037449453345572332.6614
2023-12-31GSA Capital Partners LLP0.71870.0675338986-35305-9.4325
2023-12-31Goldman Sachs Group Inc0.66240.0001312452233481295.6541
2023-12-31Susquehanna International Group, LLP0.64890.0001306069160591110.3885
2023-12-31Two Sigma Investments LLC0.63530.0016299633162163117.9625
2023-12-31Acuitas Investments, LLC0.61430.35862897662897660
2023-12-31Geode Capital Management, LLC0.48920.000123075392394.1708
Total 70.29230.880933154295+2234979+6.7%

3.2. Funds holding Kinnate Biopharma Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv1.54910.000173066300
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.56050.000626434500
2024-02-29BlackRock Health Sciences Term Trust0.41720.024919677300
2024-01-31DWS ESG Biotech LC0.24350.070311484900
2024-01-31Fidelity Extended Market Index0.21980.000710366485328.9686
2023-12-31Bridgeway Ultra-Small Company Market0.16810.101279300-65000-45.045
2024-02-29iShares U.S. Small-Cap Eq Fac ETF0.14730.01846945300
2024-02-29iShares Micro-Cap ETF0.14520.01866849600
2024-02-29Fidelity Nasdaq Composite ETF0.10730.002150593-104-0.2051
2023-09-30BlackRock Extended Mkt Composite0.06910.00033261200
2023-12-31BlackRock Extended Equity Market K0.06030.000528451-57-0.1999
2024-01-31Fidelity Total Market Index0.05770.00012723300
2024-01-31Fidelity Nasdaq Composite Index0.05610.00042645200
2024-02-29Vanguard Balanced Index Inv0.05460.00012576700
2024-02-29Dimensional US Small Cap ETF0.05430.00082560400
2024-01-31Fidelity Series Total Market Index0.05030.000123734419021.4388
2024-02-29Dimensional US Targeted Value ETF0.0450.00062122000
2024-02-29Vanguard Instl Ttl Stk Mkt Idx InstlPls0.0320.00011509100
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.0320.000115091-623072-97.6352
2023-12-31Northern Trust Extended Eq Market Idx0.02850.00061345700
Total 4.09790.24061932848-675511-34.9%

3.3. Insider Transactions

Insiders are holding 0.157% of the shares of Kinnate Biopharma Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-05-08James B TananbaumBUY17800002.8
2023-05-04Orbimed Advisors LlcBUY4799092.75
2023-05-01Carl L GordonBUY7161572.62
2023-04-28Carl L GordonBUY3507492.55

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Kinnate Biopharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---2.102-2.1020%-2.036-3%0.643-427%0.563-473%
Book Value Per Share--3.3783.3780%5.480-38%4.868-31%4.084-17%
Current Ratio--13.18713.1870%13.447-2%28.426-54%26.571-50%
Debt To Asset Ratio--0.0820.0820%0.073+13%0.287-71%0.248-67%
Debt To Equity Ratio--0.0900.0900%0.091-2%0.048+88%0.050+80%
Dividend Per Share----0%-0%-0%-0%
Eps---2.388-2.3880%-2.465+3%-1.545-35%-1.315-45%
Free Cash Flow Per Share---2.121-2.1210%-1.945-8%-1.292-39%-1.105-48%
Free Cash Flow To Equity Per Share---2.093-2.0930%-1.921-8%0.700-399%0.608-444%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---28.481--------
Intrinsic Value_10Y_min---31.884--------
Intrinsic Value_1Y_max---1.632--------
Intrinsic Value_1Y_min---2.221--------
Intrinsic Value_3Y_max---5.835--------
Intrinsic Value_3Y_min---7.557--------
Intrinsic Value_5Y_max---11.161--------
Intrinsic Value_5Y_min---13.820--------
Market Cap124990960.000+11%111784368.000111784368.0000%287715040.000-61%622313481.600-82%518594568.000-78%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio0.784+11%0.7020.7020%1.113-37%1.789-61%1.491-53%
Pe Ratio-1.110-12%-0.992-0.9920%-2.475+149%-13.049+1215%-10.874+996%
Price Per Share2.650+11%2.3702.3700%6.100-61%13.194-82%10.995-78%
Price To Free Cash Flow Ratio-1.249-12%-1.117-1.1170%-3.136+181%-15.490+1286%-12.908+1055%
Price To Total Gains Ratio-1.261-12%-1.128-1.1280%-2.997+166%-5.276+368%-5.276+368%
Quick Ratio--20.93120.9310%21.768-4%33.440-37%30.749-32%
Return On Assets---0.649-0.6490%-0.409-37%-0.309-52%-0.415-36%
Return On Equity---0.707-0.7070%-0.510-28%-0.317-55%-0.432-39%
Total Gains Per Share---2.102-2.1020%-2.036-3%0.643-427%0.563-473%
Usd Book Value--159327000.000159327000.0000%258468000.000-38%229610600.000-31%192610500.000-17%
Usd Book Value Change Per Share---2.102-2.1020%-2.036-3%0.643-427%0.563-473%
Usd Book Value Per Share--3.3783.3780%5.480-38%4.868-31%4.084-17%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---2.388-2.3880%-2.465+3%-1.545-35%-1.315-45%
Usd Free Cash Flow---100043000.000-100043000.0000%-91753000.000-8%-60926800.000-39%-52139333.333-48%
Usd Free Cash Flow Per Share---2.121-2.1210%-1.945-8%-1.292-39%-1.105-48%
Usd Free Cash Flow To Equity Per Share---2.093-2.0930%-1.921-8%0.700-399%0.608-444%
Usd Market Cap124990960.000+11%111784368.000111784368.0000%287715040.000-61%622313481.600-82%518594568.000-78%
Usd Price Per Share2.650+11%2.3702.3700%6.100-61%13.194-82%10.995-78%
Usd Profit---112649000.000-112649000.0000%-114021000.000+1%-72688800.000-35%-61845666.667-45%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---2.102-2.1020%-2.036-3%0.643-427%0.563-473%
 EOD+5 -3MRQTTM+0 -0YOY+7 -225Y+4 -2510Y+4 -25

4.2. Fundamental Score

Let's check the fundamental score of Kinnate Biopharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.110
Price to Book Ratio (EOD)Between0-10.784
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than120.931
Current Ratio (MRQ)Greater than113.187
Debt to Asset Ratio (MRQ)Less than10.082
Debt to Equity Ratio (MRQ)Less than10.090
Return on Equity (MRQ)Greater than0.15-0.707
Return on Assets (MRQ)Greater than0.05-0.649
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Kinnate Biopharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5062.607
Ma 20Greater thanMa 502.602
Ma 50Greater thanMa 1002.487
Ma 100Greater thanMa 2002.366
OpenGreater thanClose2.650
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets173,605
Total Liabilities14,278
Total Stockholder Equity159,327
 As reported
Total Liabilities 14,278
Total Stockholder Equity+ 159,327
Total Assets = 173,605

Assets

Total Assets173,605
Total Current Assets158,177
Long-term Assets15,428
Total Current Assets
Cash And Cash Equivalents 56,998
Short-term Investments 97,036
Other Current Assets 4,143
Total Current Assets  (as reported)158,177
Total Current Assets  (calculated)158,177
+/-0
Long-term Assets
Property Plant Equipment 4,760
Long Term Investments 10,259
Long-term Assets Other 38
Long-term Assets  (as reported)15,428
Long-term Assets  (calculated)15,057
+/- 371

Liabilities & Shareholders' Equity

Total Current Liabilities11,995
Long-term Liabilities2,283
Total Stockholder Equity159,327
Total Current Liabilities
Short-term Debt 892
Accounts payable 2,031
Other Current Liabilities 9,072
Total Current Liabilities  (as reported)11,995
Total Current Liabilities  (calculated)11,995
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt2,283
Long-term Liabilities  (as reported)2,283
Long-term Liabilities  (calculated)2,283
+/-0
Total Stockholder Equity
Common Stock5
Retained Earnings -372,012
Accumulated Other Comprehensive Income -12
Other Stockholders Equity 531,346
Total Stockholder Equity (as reported)159,327
Total Stockholder Equity (calculated)159,327
+/-0
Other
Capital Stock5
Cash and Short Term Investments 154,034
Common Stock Shares Outstanding 46,575
Liabilities and Stockholders Equity 173,605
Net Debt -53,823
Net Invested Capital 159,327
Net Working Capital 146,182
Property Plant and Equipment Gross 6,300
Short Long Term Debt Total 3,175



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
> Total Assets 
8,077
77,605
400,571
366,864
278,826
173,605
173,605278,826366,864400,57177,6058,077
   > Total Current Assets 
8,077
77,451
400,203
258,690
230,837
158,177
158,177230,837258,690400,20377,4518,077
       Cash And Cash Equivalents 
6,999
76,453
365,462
116,096
29,261
56,998
56,99829,261116,096365,46276,4536,999
       Short-term Investments 
0
0
31,398
103,362
172,214
97,036
97,036172,214103,36231,39800
       Net Receivables 
1,078
973
0
0
0
0
00009731,078
       Other Current Assets 
0
25
3,343
5,639
3,637
4,143
4,1433,6375,6393,343250
   > Long-term Assets 
0
154
368
108,174
47,989
15,428
15,42847,989108,1743681540
       Property Plant Equipment 
0
154
368
956
6,448
4,760
4,7606,4489563681540
       Long Term Investments 
0
0
0
105,449
39,139
10,259
10,25939,139105,449000
       Other Assets 
0
0
0
1,769
2,402
0
02,4021,769000
       Deferred Long Term Asset Charges 
0
0
0
641
0
0
00641000
> Total Liabilities 
467
95,091
7,304
12,387
20,358
14,278
14,27820,35812,3877,30495,091467
   > Total Current Liabilities 
467
1,945
7,304
12,387
17,167
11,995
11,99517,16712,3877,3041,945467
       Short-term Debt 
0
0
0
0
991
892
8929910000
       Accounts payable 
442
956
3,940
3,148
2,970
2,031
2,0312,9703,1483,940956442
       Other Current Liabilities 
25
989
3,364
9,239
13,206
9,072
9,07213,2069,2393,36498925
   > Long-term Liabilities 
0
93,146
3,940
35,000
3,191
2,283
2,2833,19135,0003,94093,1460
       Deferred Long Term Asset Charges 
0
0
0
641
0
0
00641000
       Warrants
0
0
0
35,000
35,000
0
035,00035,000000
       Deferred Long Term Liability 
0
0
0
641
0
0
00641000
> Total Stockholder Equity
7,610
-17,486
393,267
319,477
223,468
159,327
159,327223,468319,477393,267-17,4867,610
   Common Stock
0
0
4
4
4
5
544400
   Retained Earnings -372,012-259,363-143,092-53,329-17,568-7,630
   Capital Surplus 
0
0
0
463,089
484,237
0
0484,237463,089000
   Treasury Stock000000
   Other Stockholders Equity 
15,240
-93,064
46,030
463,089
484,237
531,346
531,346484,237463,08946,030-93,06415,240



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-799
Gross Profit-799-799
 
Operating Income (+$)
Gross Profit-799
Operating Expense-118,209
Operating Income-119,008-119,008
 
Operating Expense (+$)
Research Development90,767
Selling General Administrative30,003
Selling And Marketing Expenses0
Operating Expense118,209120,770
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-119,008
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-112,649-125,367
EBIT - interestExpense = -119,008
-112,649
-112,649
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-119,008-112,649
Earnings Before Interest and Taxes (EBITDA)-118,209
 
After tax Income (+$)
Income Before Tax-112,649
Tax Provision-0
Net Income From Continuing Ops-127,154-112,649
Net Income-112,649
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses119,008
Total Other Income/Expenses Net6,3590
 

Technical Analysis of Kinnate
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Kinnate. The general trend of Kinnate is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Kinnate's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Kinnate Biopharma Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 2.67 < 2.69 < 2.95.

The bearish price targets are: 2.645 > 2.52 > 2.2.

Tweet this
Kinnate Biopharma Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Kinnate Biopharma Inc. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Kinnate Biopharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Kinnate Biopharma Inc. The current macd is 0.04829849.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Kinnate price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Kinnate. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Kinnate price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Kinnate Biopharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartKinnate Biopharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Kinnate Biopharma Inc. The current adx is 34.82.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Kinnate shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Kinnate Biopharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Kinnate Biopharma Inc. The current sar is 2.57920597.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Kinnate Biopharma Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Kinnate Biopharma Inc. The current rsi is 62.61. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 3/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
Kinnate Biopharma Inc Daily Relative Strength Index (RSI) ChartKinnate Biopharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Kinnate Biopharma Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Kinnate price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Kinnate Biopharma Inc Daily Stochastic Oscillator ChartKinnate Biopharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Kinnate Biopharma Inc. The current cci is 62.49.

Kinnate Biopharma Inc Daily Commodity Channel Index (CCI) ChartKinnate Biopharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Kinnate Biopharma Inc. The current cmo is 29.54.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Kinnate Biopharma Inc Daily Chande Momentum Oscillator (CMO) ChartKinnate Biopharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Kinnate Biopharma Inc. The current willr is -23.52941176.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Kinnate is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Kinnate Biopharma Inc Daily Williams %R ChartKinnate Biopharma Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Kinnate Biopharma Inc.

Kinnate Biopharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Kinnate Biopharma Inc. The current atr is 0.04909585.

Kinnate Biopharma Inc Daily Average True Range (ATR) ChartKinnate Biopharma Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Kinnate Biopharma Inc. The current obv is 60,400,653.

Kinnate Biopharma Inc Daily On-Balance Volume (OBV) ChartKinnate Biopharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Kinnate Biopharma Inc. The current mfi is 29.43.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Kinnate Biopharma Inc Daily Money Flow Index (MFI) ChartKinnate Biopharma Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Kinnate Biopharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-10STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-15ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.

6.3. Candlestick Patterns

Kinnate Biopharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Kinnate Biopharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5062.607
Ma 20Greater thanMa 502.602
Ma 50Greater thanMa 1002.487
Ma 100Greater thanMa 2002.366
OpenGreater thanClose2.650
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Kinnate with someone you think should read this too:
  • Are you bullish or bearish on Kinnate? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Kinnate? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Kinnate Biopharma Inc

I send you an email if I find something interesting about Kinnate Biopharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Kinnate Biopharma Inc.

Receive notifications about Kinnate Biopharma Inc in your mailbox!